Equol is a Novel Anti-Androgen that Inhibits Prostate Growth and Hormone Feedback

Biology of Reproduction

Volumn 70, Issue 4, 2004, Pages 1188-1195

  Lund, Trent D ^a   Munson, Daniel J ^a   Haldy, Megan E ^a   Setchell, Kenneth D R ^b   Lephart, Edwin D ^c   Handa, Robert J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

Androgen receptor; Epididymis; Prostate; Steroid hormones; Testosterone

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; EQUOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LUTEINIZING HORMONE; PRASTERONE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; FEEDBACK SYSTEM; GROWTH INHIBITION; HORMONAL REGULATION; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MALE; NONHUMAN; ORGAN GROWTH; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE; PROSTATE VENTRAL LOBE; RAT; REPRODUCTION; SOYBEAN;

ANDROGEN ANTAGONISTS; ANIMALS; DIHYDROTESTOSTERONE; FEEDBACK, BIOCHEMICAL; GROWTH INHIBITORS; HORMONES; ISOFLAVONES; LUTEINIZING HORMONE; MALE; ORCHIECTOMY; PROSTATE; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE PROPIONATE;

ANIMALIA; GLYCINE MAX;

EID: 1642367357     PISSN: 00063363     EISSN: None     Source Type: Journal    
DOI: 10.1095/biolreprod.103.023713     Document Type: Article

References (47)

1. Adlercreutz H. Evolution, nutrition, intestinal microflora, and prevention of cancer: a hypothesis. Proc Soc Exp Biol Med 1997; 217:241-246.
2. Adlercreutz H, Mazur W. Phyto-estrogens and Western diets. Ann Med 1997; 29:95-120.
3. Setchell KDR, Zimmer-Nechemias L, Cai J, Heubi JE. Exposure of infants to phyto-estrogens from soy-based infant formula. Lancet 1997; 350:23-27.
4. Setchell KDR, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J Nutr 1999; 129:758-767.
5. Brown NM, Setchell KDR. Animal models impacted by phytoestrogens in commercial chow: implications for pathways influenced by hormones. Lab Invest 2001; 81:735-747.
6. Halbreich U, Kahn LS. Selective oestrogen receptor modulators-current and future brain and behavior applications. Expert Opin Pharmacother 2000; 1:1385-1398.
7. Coward L, Barnes NC, Setchell KDR, Barnes S. Genistein, daidzein, and their glycoside conjugates: antitumor isoflavones in soybean foods from American and Asian diets. J Agr Food Chem 1993; 41:1961-1967.
8. Price KR, Fenwick GR. Naturally occurring oestrogens in foods-a review. Food Addit Contam 1985; 2:73-106.
9. Kurzer MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr 1997; 17: 353-381.
10. Patisaul HB, Whitten PL. Dietary phytoestrogens. In: Naz RK (ed.), Endocrine Disruptors. New York: CRC Press; 1998:100-123.
11. Weber KS, Setchell KDR, Stocco DM, Lephart ED. Dietary soy-phytoestrogens decrease testosterone levels and prostate weight, without altering LH, prostate 5α-reductase or testicular StAR levels in adult male Sprague-Dawley rats. J Endocrinol 2001; 170:591-599.
12. Lephart ED, West TW, Weber KS, Rhees RW, Setchell KD, Adlercreutz H, Lund TD. Neurobehavioral effects of dietary soy phytoestrogens. Neurotoxicol Teratol 2002; 24:5-16.
13. Lephart ED, Rhees RW, Setchell KDR, Bu LH, Lund TD. Estrogens and phytoestrogens: brain plasticity of sexually dimorphic brain volumes. J Steroid Biochem Mol Biol 2003; 83:299-309.
14. Whitten PL, Patisaul HB. Cross-species and interassay comparisons of phytoestrogen action. Environ Health Perspect 2001; 1:5-20.
15. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138:863-870.
16. Kuiper GG, Lemmen JM, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1999; 139:4252-4263.
17. Petersen DN, Tkalcevic GT, Koza-Taylor PH, Turi TG, Brown TA. Identification of estrogen receptor 2, a functional variant of estrogen receptor expressed in normal rat tissues. Endocrinology 1998; 139: 1082-1092.
18. Hol T, Cox MB, Bryant HU, Draper MW. Selective estrogen receptor modulators and postmenopausal women's health. J Womens Health 1997; 6:523-531.
19. Whitten PL, Naftolin F. Reproductive actions of phytoestrogens. Baillieres Clin Endocrinol Metab 1998; 12:667-690.
20. Marrian G, Haslewood G. Equol, a new inactive phenol isolated from the ketohydroxyestrin fraction of mares urine. Biochem J 1932; 26: 1227-1232.
21. Martin L. Further studies on the use of tetrazolium in the bioassay of oestrogens. J Endocrinol 1964; 30:21-31.
22. Shutt D, Braden A. The significance of equol in relation to the oestrogenic responses in sheep ingesting clover with a high formononetin content. Aust J Agric Res 1968; 19:545-553.
23. Medlock KL, Branham WS, Sheehan DM. Effects of coumetarol and equol on the developing reproductive tract of the rat. Proc Soc Exp Biol Med 1995; 208:67-71.
24. Medlock KL, Branham WS, Sheehan DM. The effects of phytoestrogens on neonatal rat uterine growth and development. Proc Soc Exp Biol Med 1995; 208:307-313.
25. Morito K, Hirose T, Kinjo J, Hirakawa T, Okawa M, Nohara T, Ogawa S, Inoue S, Muramatsu M, Masamune Y. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull 2001; 24: 351-356.
26. Dechaud H, Ravard C, Claustrat F, de la Perriere AB, Pugeat M. Xenoestrogen interaction with human sex hormone-binding globulin (hSHBG). Steroids 1998; 64:328-334.
27. Martin ME, Haourigui M, Pelissero C, Benassayag C, Nunez EA. Interactions between phytoestrogens and human sex steroid binding protein. Life Sci 1996; 58:429-436.
28. Garreau B, Vallette G, Adlercreutz H, Wahala K, Makela T, Benassayag C, Nunez EA. Phytoestrogens: new ligands for rat and human alpha-fetoprotein. Biochim Biophys Acta 1991; 1094:339-345.
29. Arora A, Nair MG, Strasburg GM. Antioxidant activities of isoflavones and their biological metabolites in a liposomal system. Arch Biochem Biophys 1998; 356:133-141.
30. Hodgson JM, Puddey IB, Croft KD, Mori TA, Rivera J, Beilin LJ. Isoflavonoids do not inhibit in vivo lipid peroxidation in subjects with high-normal blood pressure. Atherosclerosis 1999; 145:167-172.
31. Mitchell JH, Gardner PT, McPhail DB, Morrice PC, Collins AR, Duthie GG. Antioxidant efficacy of phytoestrogens in chemical and biological model systems. Arch Biochem Biophys 1998; 360:142-148.
32. Hedlund TE, Johannes WU, Miller GJ. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 2003; 54:68-78.
33. O'Keefe JA, Handa RJ. Transient elevation of estrogen receptors in the neonatal rat hippocampus. Dev Brain Res 1990; 57:119-127.
34. Handa RJ, Reid DL, Resko JA. Androgen receptor in brain and pituitary of female rats: cyclic changes and comparisons with the male. Biol Reprod 1986; 34:293-303.
35. Handa RJ, Roselli CE, Horton L, Resko JA. The quantitative distribution of cytosolic androgen receptor in microdissected areas of the male rat brain: effects of estrogen treatment. Endocrinology 1987; 121:233-240.
36. Setchell KD, Brown N, Lydeking-Olsen N. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 2002; 132:3577-3584.
37. Griffiths K, Morton MS, Nicholson RI. Androgens, androgen receptors, antiandrogens, and the treatment of prostate cancer. Eur Urol 1997; 32(suppl 3):24-40.
38. Steers WD. 5alpha-reductase activity in the prostate. Urology 2001; 58:17-24.
39. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, Mori M. Is a daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 2002; 32:296-300.
40. Nagamoto A, Noguchi K, Murai T, Kinoshita Y. Significant role of 5 alpha-reductase on feedback effects of androgen in rat anterior pituitary cells demonstrated with a nonsteroidal 5 alpha-reductase inhibitor ONO-3805. J Androl 1994; 15:521-527.
41. Zoppi S, Cocconi M, Lechuga MJ, Messi E, Zanisi M, Motta M. Antihormonal activities of 5 alpha-reductase and aromatase inhibitors. J Steroid Biochem 1988; 31:677-683.
42. Tenover JS. Prostates, pates, and pimples. The potential medical uses of steroid 5 alpha-reductase inhibitors. Endocrinol Metab Clin North Am 1991; 20:893-909.
43. Trueb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol 2002; 37:981-990.
44. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000; 21:347-362.
45. Labrie F, Luu-The V, Labrie C, Pelletier G, El-Alfy M. Intracrinology and the skin. Horm Res 2000; 54:218-229.
46. Fink G, Sumner B, Rosie R, Wilson H, McQueen J. Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory. Behav Brain Res 1999; 105:53-68.
47. Fink G, Sumner BE, McQueen JK, Wilson H, Rosie R. Sex steroid control of mood, mental state and memory. Clin Exp Pharmacol Physiol 1998; 25:764-775.